secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation

Oncology Research

Volumn 14, Issue 11-12, 2004, Pages 589-602

  Gilmore, Jennifer L ^a   Riese II, David J ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Antagonist; ErbB3; ErbB4; Neuregulin

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; LIGAND; NEU DIFFERENTIATION FACTOR; PROTEIN; PROTEIN SECERBB4 26 549; PROTEIN TYROSINE KINASE; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; EXTRACELLULAR DOMAIN; IN VIVO STUDY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 13144255725     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/0965040042707907     Document Type: Article

References (74)

1. Kumar, R.; Vadlamudi, R.K. The EGF family of growth factors. J. Clin. Ligand Assay 23:233-238; 2000.
2. Gullick, W. J. The type 1 growth factor receptors and their ligands considered as a complex system. Endocr. Relat. Cancer 8:75-82; 2001.
3. Yarden, Y.; Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2:127-137; 2001.
4. Stern, D. F. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2:176-183; 2000.
5. Normanno, N.; Bianco, C.; De Luca, A.; Salomon, D. S. The role of EGF-related peptides in tumor growth. Front. Biosci. 6:D685-707; 2001.
6. Ozawa, F.; Friess, H.; Tempia-Caliera, A.; Kleeff, J.; Buchler, M. W. Growth factors and their receptors in pancreatic cancer. Teratog. Carcinog. Mutagen. 21:27-44; 2001.
7. Ravdin, P. M.; Chamness, G. C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - a review. Gene 159:19-27; 1995.
8. Mendelsohn, J.; Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565; 2000.
9. Slamon, D.; Pegram, M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin. Oncol. 28: 13-19; 2001.
10. Yu, D.; Hung, M. C. Role of erbB2 in breast cancer chemosensitivity. Bioessays 22:673-680; 2000.
11. Simon, R.; Nocito, A.; Hubscher, T.; Bucher, C.; Torhorst, J.; Schraml, P.; Bubendorf, L.; Mihatsch, M.; Moch, H.; Wilber, K.; Schotzau, A.; Kononen, J.; Sauter, G. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl. Cancer Inst. 93:1141-1146; 2001.
12. Thor, A. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? J. Natl. Cancer Inst. 93:1120-1121; 2001.
13. Tsongalis, G. J.; Ried, A., Jr. HER2: The neu prognostic marker for breast cancer. Crit. Rev. Clin. Lab. Sci. 38: 167-182; 2001.
14. Bacus, S. S.; Chin, D.; Yarden, Y.; Zelnick, C. R.; Stern, D. F. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am. J. Pathol. 148:549-558; 1996.
15. Kew, T. Y.; Bell, J. A.; Pinder, S. E.; Denley, H.; Srinivasan, R.; Gullick, W. J.; Nicholson, R. I.; Blamey, R. W.; Ellis, I. O. c-erbB-4 protein expression in human breast cancer. Br. J. Cancer 82:1163-1170; 2000.
16. Srinivasan, R.; Gillett, C. E.; Barnes, D. M.; Gullick, W. J. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res. 60: 1483-1487; 2000.
17. Suo, Z.; Risberg, B.; Kalsson, M. G.; Willman, K.; Tierens, A.; Skovlund, E.; Nesland, J. M. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J. Pathol. 196: 17-25; 2002.
18. Witton, C. J.; Reeves, J. R.; Going, J. J.; Cooke, T. G.; Bartlett, J. M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 200:290-297; 2003.
19. Williams, E. E.; Trout, L. J.; Gallo, R. M.; Pitfield, S. E.; Bryant, I.; Penington, D. J.; Riese, D. J., 2nd. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett. 192:67-74; 2003.
20. Kita, Y. A.; Barff, J.; Luo, Y.; Wen, D.; Brankow, D.; Hu, S.; Liu, N.; Prigent, S. A.; Gullick, W. J.; Nicolson, M. NDF/heregulin stimulates the phosphorylation of Her3/ erbB3. FEBS Lett. 349:139-143; 1994.
21. Lu, H. S.; Chang, D.; Philo, J. S.; Zhang, K.; Narhi, L. O.; Liu, N.; Zhang, M.; Sun, J.; Wen, J.; Yanagihara, D. Studies on the structure and function of glycosylated and nonglycosylated neu differentiation factors. Similarities and differences of the alpha and beta isoforms. J. Biol. Chem. 270:4784-4791; 1995.
22. Riese, D. J., 2nd; van Raaij, T. M.; Plowman, G. D.; Andrews, G. C.; Stern, D. F. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol. Cell. Biol. 15:5770-5776; 1995.
23. Riese, D. J., 2nd; Bermingham, Y.; van Raaij, T. M.; Buckley, S.; Plowman, G. D.; Stern, D. F. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Oncogene 12:345-353; 1996.
24. Pinkas-Kramarski, R.; Shelly, M.; Guarino, B. C.; Wang, L. M.; Lyass, L.; Alroy, I.; Alimandi, M.; Kuo, A.; Moyer, J. D.; Lavi, S.; Eisenstein, M.; Ratzkin, B. J.; Seger, R.; Bacus, S. S.; Pierce, J. H.; Andrews, G. C.; Yarden, Y.; Alamandi, M. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol. Cell. Biol. 18:6090-6101; 1998.
25. Pinkas-Kramarski, R.; Shelly, M.; Guarino, B. C.; Wang, L. M.; Lyass, L.; Alroy, I.; Alimandi, M.; Kuo, A.; Moyer, J. D.; Lavi, S.; Eisenstein, M.; Ratzkin, B. J.; Seger, R.; Bacus, S. S.; Pierce, J. H.; Andrews, G. C.; Yarden, Y.; Alamandi, M. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol. Cell. Biol. 19:8695; 1999.
26. Jones, J. T.; Akita, R. W.; Sliwkowski, M. X. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 447:227-231; 1999.
27. Sweeney, C.; Lai, C.; Riese, D. J., 2nd; Diamonti, A. J.; Cantley, L. C.; Carraway, K. L., 3rd. Ligand discrimination in signaling through an ErbB4 receptor homodimer. J. Biol. Chem. 275:19803-9807; 2000.
28. Hobbs, S. S.; Coffing, S. L.; Le, A. T.; Cameron, E. M.; Williams, E. E.; Andrew, M.; Blommel, E. N.; Hammer, R. P.; Chang, H.; Riese, D. J., 2nd. Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 21:8442-8452; 2002.
29. Zhang, D.; Sliwkowski, M. X.; Mark, M.; Frantz, G.; Akita, R.; Sun, Y.; Hillan, K.; Crowley, C.; Brush, J.; Godowski, P. J. Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4. Proc. Natl. Acad. Sci. USA 94:9562-9567; 1997.
30. Harari, D.; Tzahar, E.; Romano, J.; Shelly, M.; Pierce, J. H.; Andrews, G. C.; Yarden, Y. Neuregulin-4: A novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 18:2681-2689; 1999.
31. Carraway, K. L., 3rd; Cantley, L. C. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling. Cell 78:5-8; 1994.
32. Riese, D. J., 2nd; Komurasaki, T.; Plowman, G. D.; Stern, D. F. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. J. Biol. Chem. 273:11288-11294; 1998.
33. Amin, D. N.; Perkins, A. S.; Stern, D. F. Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene 23:1428-1438; 2004.
34. Jones, F. E.; Welte, T.; Fu, X. Y.; Stern, D. F. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J. Cell. Biol. 147:77-88; 1999.
35. Penington, D. J.; Bryant, I.; Riese, D. J., 2nd. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ. 13:247-256; 2002.
36. Tang, C. K.; Goldstein, D. J.; Payne, J.; Czubayko, F.; Alimandi, M.; Wang, L. M.; Pierce, J. H.; Lippman, M. E. ErbB-4 ribozymes abolish neuregulin-induced mitogenesis. Cancer Res. 58:3415-3422; 1998.
37. Tang, C. K.; Concepcion, X. Z.; Milan, M.; Gong, X.; Montgomery, E.; Lippman, M. D. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res. 59:5315-5322; 1999.
38. Gassmann, M.; Casagranda, F.; Orioli, D.; Simon, H.; Lai, C.; Klein, R.; Lemke, G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378:390-394; 1995.
39. Jones, F. E.; Golding, J. P.; Gassmann, M. ErbB4 signaling during breast and neural development: Novel genetic models reveal unique ErbB4 activities. Cell Cycle 2:555-559; 2003.
40. Long, W.; Wagner, K. U.; Lloyd, K. C.; Binait, N.; Shillingford, J. M.; Hennighausen, L.; Jones, F. E. Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 130:5257-5268; 2003.
41. Tidcombe, H.; Jackson-Fisher, A.; Mathers, K.; Stern, D. F.; Gassmann, M.; Golding, J. P. Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc. Natl. Acad. Sci. USA 100: 8281-8286; 2003.
42. Ni, C. Y.; Murphy, M. P.; Golde, T. E.; Carpenter, G. γ-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294:2179-2181; 2001.
43. Vecchi, M.; Carpenter, G. Constitutive proteolysis of the ErbB4 receptor tyrosine kinase by a unique, sequential mechanism. J. Cell Biol. 139:995-1003; 1997.
44. Vecchi, M.; Baulida, J.; Carpenter, G. Selective cleavage of the heregulin receptor ErB4 by protein kinase C activation. J. Biol. Chem. 271:18989-18995; 1996.
45. Lee, H. J.; Jung, K. M.; Huang, Y. Z.; Bennett, L. B.; Lee, J. S.; Mei, L.; Kim, T. W. Presenilin-dependent γ-secretase-like intramembrane cleavage of ErbB4. J. Biol. Chem. 277:6318-6323; 2002.
46. Zhou, W.; Carpenter, G. Heregulin-dependent trafficking and cleavage of ErbB-4. J. Biol. Chem. 275:34737-34743; 2000.
47. Komuro, A.; Nagai, M.; Navin, N. E.; Sudol, M. WW domain-containing YAP associates with ErbB4 and acts a a co-transcriptional activator for the carboxyl-terminal fragment of ErbB4 that translocates to the nucleus. J. Biol. Chem. 278:33334-33341; 2003.
48. Fitzpatrick, V. D.; Pisacane, P. I.; Vandlen, R. L.; Sliwkowski, M. X. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett. 431:102-106; 1998.
49. Ferguson, K. M.; Darling, P. J.; Mohan, M. J.; Macatee, T. L.; Lemmon, M. A. Extracellular domains drive homo-but not heterodimerization of erbB receptors. EMBO J. 19:4632-4643; 2000.
50. Lee, H.; Akita, R. W.; Sliwkowski, M. X.; Maihle, N. J. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res. 61:4467-4473; 2001.
51. Plowman, G. D.; Green, J. M.; Culouscou, J. M.; Carlton, G. W.; Rothwell, V. M.; Buckley, S. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 366:473-475; 1993.
52. Hobbs, S. S.; Cameron, E. M.; Hammer, R. P.; Le, A. T.; Gallo, R. M.; Blommel, E. N.; Coffing, S. L.; Chang, H.; Riese, D. J., 2nd. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene 23:883-893; 2004.
53. Feroz, K.; Williams, E.; Riese, D. J., 2nd. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation. Cell. Signal. 14:793-798; 2002.
54. Riese, D. J., 2nd; Kim, E. D.; Elenius, K.; Buckley, S.; Klagsbrun, M.; Plowman, G. D.; Stern, D. F. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. J. Biol. Chem. 271:20047-20052; 1996.
55. Chang, H.; Riese, D. J., 2nd; Gilbert, W.; Stern, D. F.; McMahan, U. J. Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature 387:509-512; 1997.
56. Mu, F.; Coffing, S. L.; Riese, D. J., 2nd; Geahlen, R. L.; Verdier-Pinard, P.; Hamel, T. E.; Johnson, J.; Cushman, M. Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization. J. Med. Chem. 44:441-452; 2001.
57. Lax, I.; Burgess, W. H.; Bellot, F.; Ullrich, A.; Schlessinger, J.; Givol, D. Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol. Cell. Biol. 8:1831-1834; 1988.
58. Plowman, G. D.; Culouscou, J. M.; Whitney, G. S.; Green, J. M.; Carlton, G. W.; Foy, L.; Neubauer, M. G.; Shoyab, M. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA 90:1746-1750; 1993.
59. Cho, H. S.; Leahy, D. J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297: 1330-1333; 2002.
60. Burgess, A. W.; Cho, H. S.; Eigenbrot, C.; Ferguson, K. M.; Garrett, T. P.; Leahy, D. J.; Lemmon, M. A.; Sliwkowski, M. X.; Ward, C. W.; Yokoyama, S. An open-and-shut case? Recent insights into the activation of EGF/ ErbB receptors. Mol. Cell 12:541-552; 2003.
61. Ferguson, K. M.; Berger, M. B.; Mendrola, J. M.; Cho, H. S.; Leahy, D. J.; Lemmon, M. A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 11:507-517; 2003.
62. Sliwkowski, M. X.; Schaefer, G.; Akita, R. W.; Lofgren, J. A.; Fitzpatrick, V. D.; Nuijens, A.; Fendly, B. M.; Cerione, R. A.; Vandlen, R. L.; Carraway, K. L., 3rd. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269:14661-14665; 1994.
63. Stern, D. F.; Kamps, M. P. EGF-stimulated tyrosine phosphorylation of p185neu: A potential model for receptor interactions. EMBO J. 7:995-1001; 1988.
64. Riese, D. J., 2nd; Stern, D. F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20:41-48; 1998.
65. Basu, A.; Raghunath, M.; Bishayee, S.; Das, M. Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: Role for interreceptor interaction in kinase regulation. Mol. Cell. Biol. 9:671-677; 1989.
66. Redemann, N.; Holzmann, B.; von Ruden, T.; Wagner, E. F.; Schlessinger, J.; Ullrich, A. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol. Cell. Biol. 12:491-498; 1992.
67. Ram, T. G.; Schelling, M. E.; Hosick, H. L. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification. Cell Growth Differ. 11:173-183; 2000.
68. Elleman, T. C.; Domagala, T.; McKern, N. M.; Nerrie, M.; Lonnqvist, B.; Adams, T. E.; Lewis, J.; Lovrecz, G. O.; Hoyne, P. A.; Richards, K. M.; Howlett, G. J.; Rothacker, J.; Jorissen, R. N.; Lou, M.; Garrett, T. P.; Burgess, A. W.; Nice, E. C.; Ward, C. W. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry 40:8930-8939; 2001.
69. Azios, N. G.; Romero, F. J.; Denton, M. C.; Doherty, J. K.; Clinton, G. M. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene 20:5199-209; 2001.
70. Meyer, D.; Birchmeier, C. Multiple essential functions of neuregulin in development. Nature 378:386-390; 1995.
71. Garrett, T. P.; McKern, N. M.; Lou, M.; Elleman, T. C.; Adams, T. E.; Lovrecz, G. O.; Zhu, H. J.; Walker, F.; Frenkel, M. J.; Hoyne, P. A.; Jorissen, R. N.; Nice, E. C.; Burgess, A. W.; Ward, C. W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110: 763-773; 2002.
72. Ogiso, H.; Ishitani, R.; Nureki, O.; Fukai, S.; Yamanaka, M.; Kim, J. H.; Saito, K.; Sakamoto, A.; Inoue, M.; Shirouzu, M.; Yokoyama, S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775-787; 2002.
73. Ullrich, A.; Bell, J. R.; Chen, E. Y.; Herrera, R.; Petruzzelli, L. M.; Dull, T. J.; Gray, A.; Coussens, L.; Liao, Y. C.; Tsubokawa, M. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313:756-761; 1985.
74. Bajaj, M.; Waterfield, M. D.; Schlessinger, J.; Taylor, W. R.; Blundell, T. On the tertiary structure of the extracellular domains of the epidermal growth factor and insulin receptors. Biochim. Biophys. Acta 916:220-226; 1987.